Company news: KnowledgePoint360, TGaS Advisors, United Business Media and Canon Communications

Share this article:

KnowledgePoint360 acquired TGaS Advisors, provider of data and advice to pharma sales and marketing organizations, broadening the private firm's holdings. Terms of the deal were not disclosed. TGaS will become an operating division of the company, and its managing director, Stephen Gerard, will continue as president. KnowledgePoint360—whose other divisions support publication plans, speakers bureau logistics, disease-state education and other medical-communications services—was created after the 2007 acquisition of Thomson Medical Education (TME) by KnowledgePoint360's majority owner, private-equity firm ABRY Partners. Last year the firm closed one former TME division, Postgraduate Professional Services (PPS), its accredited medical-education arm. "Through investments in our existing business, we have been continually adding to our services; this year alone, we have greatly enlarged our digital services division (eMedFusion), launched a consulting division (Interphase), and begun a nursing education initiative (NUCLEUS)," Jon Bigelow, president and CEO of KnowledgePoint360, told MM&M by email. Bigelow added, "The benchmark-based advisory services of TGaS Advisors represent a logical diversification for our company, complementing rather than duplicating our existing offerings but still focused on our mission of finding innovative ways to develop and deliver immediately-useful healthcare information."

United Business Media acquired Canon Communications, owner of Med Ad News, for $287 million. It's the biggest of some 80 acquisitions the company has made under the leadership of CEO David Levin, who took the reins in 2005, Dow Jones Newswires reported.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.